Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingSummaCare Melanoma Assay Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Melanoma Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of molecular and gene-expression assays used for the diagnosis, risk stratification, or management of uveal and cutaneous melanoma for SummaCare commercial and Medicare members. Self-funded commercial groups must refer to their plan documents for coverage.

    Policy Summary
    PayerSummaCare
    PolicyMelanoma Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date10/8/26
    Next Review DateN/A
    Key ActionFor commercial DecisionDx-UM, confirm primary localized uveal melanoma without metastatic disease, no prior successfully obtained post-diagnosis test, and use of a qualified rendering laboratory.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Plans covered
    81552Listed CPT code
    15Genes in coded assay
    3Named testing applications
    5 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Risk period assessed

    Coverage Criteria

    Commercial DecisionDx-UM

    Commercial DecisionDx-UM is medically necessary when ALL of the following are met.

    Commercial DecisionDx-UM criteria

    • No duplicate testing: No previous DecisionDx-UM testing was performed after the current diagnosis when a result was successfully obtained.
    • Localized uveal melanoma: The member has primary, localized uveal melanoma.
    • No metastatic disease: There is no evidence of metastatic disease.
    • Qualified laboratory: The rendering laboratory is a qualified provider.

    Medicare Cutaneous Melanoma Molecular Assays

    Medicare molecular DNA/RNA assays for diagnosis or exclusion of melanoma from a biopsy are covered only when ALL of the following conditions are met.

    Medicare cutaneous melanoma assay criteria

    • Qualified ordering clinician: The test is ordered by a board-certified or board-eligible dermatopathologist.
    • Equivocal primary specimen: The specimen is a primary, non-metastatic, non-re-excision cutaneous melanocytic neoplasm for which the diagnosis is equivocal or uncertain; a clear distinction between benign and malignant cannot be achieved using clinical and/or histopathological features alone despite standard-of-care test procedures and relevant ancillary tests, including immunohistochemical stains.
    • Representative suspicious lesion: The specimen includes an area representative of the lesion or a portion of the lesion that is suspicious for malignancy.

    Medicare DecisionDx-UM

    Medicare provides limited coverage for DecisionDx-UM for management of newly diagnosed uveal melanoma.

    Medicare DecisionDx-UM use

    • Confirmed uveal melanoma without metastasis: The patient has a confirmed diagnosis of uveal melanoma and no evidence of metastatic disease.
    • Covered management purpose: The test is used to determine metastatic risk and guide surveillance and referral to medical oncology, preferably an oncologist with expertise in melanoma.

    Use of myPath Melanoma as a guide for treatment-management decisions is not supported because evidence is insufficient to establish a positive impact on health outcomes.

    Evidence is insufficient to support use of DecisionDx-UM to determine the likelihood of metastasis within five years. Although an assay process is established, the test’s validity and impact on patient management remain unclear.

    Use of myPath Melanoma to guide treatment decisions is not supported as medically necessary by the available evidence.

    Use of DecisionDx-UM to identify metastatic risk is not supported as medically necessary when the validity of the result or its impact on patient management has not been established.

    Covered Coding

    Covered CPT CodesCPTCovered
    81552Oncology (uveal melanoma), mrna, gene expression profiling by real-time rt-pcr of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffinembedded tissue, algorithm reported as risk of metastasis

    Documentation and Authorization Requirements

    Prior Authorization

    Commercial DecisionDx-UM Authorization Criteria

    For commercial members, SummaCare considers DecisionDx-UM medically necessary for management of newly diagnosed uveal melanoma when the stated clinical eligibility requirements are met. The test is intended to determine metastatic risk and guide surveillance and referral to medical oncology, preferably a melanoma specialist.

    • Confirmed diagnosis of uveal melanoma.
    • Primary, localized disease with no evidence of metastatic disease.
    • No prior DecisionDx-UM testing after the current diagnosis when a result was successfully obtained.
    • Testing performed by a qualified rendering laboratory.
    Documentation Required

    Commercial Uveal Melanoma Documentation

    Document the clinical facts supporting commercial DecisionDx-UM testing, including the confirmed uveal melanoma diagnosis, localized status, metastatic evaluation, prior testing history, and the qualified laboratory performing the assay.

    Clinical Background

    Melanoma molecular assays have different intended applications. myPath Melanoma evaluates expression of 23 genes as an adjunct when histopathology cannot confidently distinguish a benign nevus from melanoma. DecisionDx-Melanoma evaluates 28 genes to classify recurrence or metastasis risk, while DecisionDx-UM evaluates uveal melanoma tissue to estimate metastatic risk and guide surveillance and referral to medical oncology.

    Test and Clinical Definitions

    myPath Melanoma
    Intended useAdjunct to histopathology when the distinction between a benign nevus and malignant melanoma cannot be made confidently by histopathology alone.
    Testing methodGene-expression test using qRT-PCR methodology.
    Genes measured23 genes.
    DecisionDx-Melanoma
    Test typeMultigene expression test analyzing 28 genes with differential expression between metastatic and nonmetastatic melanoma tumors.
    SpecimenFormalin-fixed paraffin-embedded tumor tissue from the patient's primary cutaneous melanoma tumor.
    Purpose

    Covered Clinical Indications

    Newly Diagnosed Primary Localized Uveal Melanoma

    DecisionDx-UM is covered for management of newly diagnosed disease when ALL of the following are met.

    Newly diagnosed primary localized uveal melanoma

    • Confirmed diagnosis: The patient has a confirmed diagnosis of uveal melanoma.
    • Primary localized disease: The uveal melanoma is primary and localized.
    • No metastatic disease: There is no evidence of metastatic disease.
    • Metastatic-risk management purpose:

    Eligibility Requirements

    For Medicare cutaneous melanoma molecular assays, the patient must not have undergone the same or a similar assay for the same clinical indication. The specimen must be an equivocal primary, non-metastatic, non-re-excision cutaneous melanocytic neoplasm despite standard-of-care evaluation and relevant ancillary testing, and the assay must meet the applicable ordering, specimen, validation, clinical utility, analytical and clinical validity, and MolDx technical-assessment requirements.

    Noncovered and Unsupported Uses

    Not covered: Use of myPath Melanoma as a guide for treatment-management decisions is unsupported because evidence is insufficient to establish a positive impact on health outcomes. Use of DecisionDx-UM to determine metastatic risk is not supported when test validity and the impact on patient management remain unclear.

    Policy Summary
    PayerSummaCare
    PolicyMelanoma Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date10/8/26
    Next Review DateN/A
    Key ActionFor commercial DecisionDx-UM, confirm primary localized uveal melanoma without metastatic disease, no prior successfully obtained post-diagnosis test, and use of a qualified rendering laboratory.
    SourceLink
    On This Page
    Coverage CriteriaCovered CodingDocumentation and Authorization RequirementsClinical BackgroundTest and Clinical DefinitionsCovered Clinical IndicationsEligibility RequirementsNoncovered and Unsupported Uses
    Potential additional intervention:
    The patient may undergo additional intervention, such as re-excision and/or sentinel lymph node biopsy, as a result of the diagnostic uncertainty.
  1. No duplicate assay: The patient has not been tested with the same or similar assay for the same clinical indication.
  2. Validated intended use: The test is validated for use in the intended-use population and is performed according to its stated intended use.
  3. Validity, utility, and technical assessment: The test demonstrates analytical validity, clinical validity, and clinical utility and undergoes a technical assessment by MolDx to demonstrate compliance of the service with this policy.
    • Record that the patient has newly diagnosed uveal melanoma.
    • Document that disease is primary and localized and that there is no evidence of metastasis.
    • Identify whether DecisionDx-UM was previously performed after the current diagnosis and whether a result was successfully obtained.
    • Document the intended use for metastatic-risk assessment, surveillance planning, and medical-oncology referral.
    Documentation Required

    Medicare Assay Documentation

    For Medicare members, coverage is limited to the applicable CMS CGS MolDX guidance. Documentation must establish the clinical uncertainty, standard diagnostic workup, specimen characteristics, potential management consequence, prior testing status, and assay performance requirements.

    • DecisionDx-UM: confirmed newly diagnosed uveal melanoma with no evidence of metastatic disease; testing is for metastatic-risk determination, surveillance, and referral to medical oncology.
    • Cutaneous melanoma assay: primary, non-metastatic, non-re-excision cutaneous melanocytic neoplasm with an equivocal or uncertain diagnosis despite standard-of-care procedures and relevant ancillary testing, including immunohistochemical stains.
    • Specimen must include an area representative of the lesion or the portion suspicious for malignancy.
    • Diagnostic uncertainty must be capable of resulting in additional intervention, such as re-excision or sentinel lymph node biopsy.
    • The patient must not have had the same or a similar assay for the same clinical indication.
    • The assay must be validated for the intended-use population, performed according to its stated intended use, and demonstrate analytical validity, clinical validity, and clinical utility.
    • The service must undergo MolDx technical assessment demonstrating compliance with the policy.
    Denial Risk

    Commercial DecisionDx-UM Denial Conditions

    Commercial DecisionDx-UM authorization should be denied or considered not medically necessary when the eligibility requirements are not satisfied, including when the disease is metastatic or is not primary and localized.

    • Evidence of metastatic uveal melanoma.
    • No confirmed primary localized uveal melanoma diagnosis.
    • A prior DecisionDx-UM test was performed after the current diagnosis and a result was successfully obtained.
    • The rendering laboratory is not a qualified provider.
    • The requested use is outside metastatic-risk assessment, surveillance guidance, or referral to medical oncology for newly diagnosed disease.
    Denial Risk

    Medicare Cutaneous Melanoma Assay Limitations

    Medicare coverage for cutaneous melanoma molecular assays is limited to the policy-defined diagnostic situation and technical requirements. Claims may be denied when the ordering provider, specimen, diagnosis, workup, intended use, validation, or MolDx technical requirements are not documented or satisfied.

    • The assay is not ordered by a board-certified or board-eligible dermatopathologist.
    • The specimen is metastatic, a re-excision specimen, or otherwise not a primary cutaneous melanocytic neoplasm.
    • The diagnosis is not equivocal or uncertain after standard-of-care clinical and histopathological evaluation and relevant ancillary testing.
    • The specimen does not contain a representative or malignancy-suspicious portion of the lesion.
    • The diagnostic uncertainty is not reasonably expected to lead to additional intervention, such as re-excision or sentinel lymph node biopsy.
    • The patient received the same or a similar assay for the same clinical indication.
    • The assay is not validated for the intended-use population, is not performed according to its stated intended use, or lacks demonstrated analytical validity, clinical validity, clinical utility, or required MolDx technical assessment.
    Denial Risk

    Insufficient Evidence for Management Use

    There is insufficient evidence to support using these assays to guide treatment or management decisions. Such uses may be denied or treated as noncovered because clinical validity, clinical utility, and impact on health outcomes are not adequately established.

    • myPath Melanoma: evidence is limited for use as a diagnostic adjunct to distinguish benign nevi from melanoma when histopathology is ambiguous, and insufficient to support guiding treatment decisions or demonstrating improved health outcomes.
    • DecisionDx-UM: insufficient evidence supports use to identify the likelihood of metastasis within five years in patients with uveal melanoma; the validity and impact on patient management remain unclear.
    • Do not use assay results alone to direct treatment decisions or assume coverage for management applications outside the applicable coverage criteria.
    Documentation Required

    Provider Action: Medicare Cutaneous Melanoma Assays

    The Medicare cutaneous melanoma assay must be ordered by a board-certified or board-eligible dermatopathologist. The ordering provider should include complete documentation of diagnostic uncertainty, the required clinical and ancillary workup, representative specimen findings, anticipated intervention, prior assay history, and compliance with validation and MolDx technical requirements.

    • Confirm and document the ordering dermatopathologist's board certification or board-eligibility.
    • Include the pathology and clinical records supporting an equivocal or uncertain diagnosis after standard-of-care testing and relevant ancillary tests.
    • Document specimen type and representative lesion tissue, potential additional intervention, prior same-or-similar assay testing, intended use, validation, and MolDx technical assessment.
    Classifies recurrence and/or metastasis risk within five years of diagnosis.
    Risk classificationLow (Class 1A), intermediate (Class 1B or 2A), or high (Class 2B) risk.
    DecisionDx-UM
    Test typeMolecular test for newly diagnosed uveal melanoma.
    Risk assessmentDetermines metastatic risk in patients with confirmed uveal melanoma and no evidence of metastatic disease.
    Clinical useGuides surveillance and referral to medical oncology, preferably an oncologist with expertise in melanoma.
    Equivocal or uncertain melanocytic neoplasm
    DefinitionA primary, non-metastatic, non-re-excision cutaneous melanocytic biopsy specimen for which a clear distinction between benign and malignant cannot be achieved using clinical and/or histopathological features alone.
    Required evaluationThe classification remains unresolved despite standard-of-care test procedures and relevant ancillary tests, including immunohistochemical stains.
    Specimen characteristicThe specimen includes an area representative of the lesion or a portion of the lesion suspicious for malignancy.
    The test is used to determine metastatic risk and guide surveillance and referral to medical oncology, preferably an oncologist with expertise in melanoma.

    Equivocal Primary Cutaneous Melanocytic Neoplasm

    Molecular DNA/RNA assays are covered for diagnosis or exclusion of cutaneous melanoma when ALL of the following requirements are met.

    Equivocal primary cutaneous melanocytic neoplasm

    • Qualified ordering clinician: The test is ordered by a board-certified or board-eligible dermatopathologist.
    • Equivocal diagnosis after standard evaluation: The specimen is a primary, non-metastatic, non-re-excision cutaneous melanocytic neoplasm for which benign versus malignant distinction remains equivocal or uncertain despite standard-of-care test procedures and relevant ancillary tests, including immunohistochemical stains.
    • Representative suspicious specimen: The specimen includes an area representative of the lesion or a portion of the lesion suspicious for malignancy.
    • Potential impact on intervention: The patient may undergo additional intervention, such as re-excision and/or sentinel lymph node biopsy, as a result of the diagnostic uncertainty.
    • No prior similar assay: The patient has not been tested with the same or similar assay for the same clinical indication.
    • Intended-use validation: The test is validated for use in the intended-use population and is performed according to its stated intended use.
    • Analytical and clinical requirements: The test demonstrates analytical validity, clinical validity, and clinical utility.
    • MolDx technical assessment: The test undergoes a technical assessment by MolDx to demonstrate compliance of the service with this policy.